Targeted Cancer Therapy with Enhanced Conjugate Delivery
Legal Citation
Summary of the Inventive Concept
This next-generation technology combines a conjugate of formula (I) with advanced targeting moieties, companion diagnostics, and biomarker monitoring to create a more effective and personalized cancer treatment.
Background and Problem Solved
The original patent disclosed anti-CD25 antibody-maytansine conjugates, but these may have limited efficacy and specificity in certain cancer patients. The new inventive concept addresses these limitations by introducing nucleic acid aptamers, CD25-binding peptides, and microfluidic reactors to enhance conjugate delivery, targeting, and monitoring.
Detailed Description of the Inventive Concept
The inventive concept comprises a conjugate of formula (I) linked to a targeting moiety, such as a nucleic acid aptamer specific for a cancer cell surface receptor. This conjugate is administered in combination with a companion diagnostic test for detecting CD25 expression levels in the patient. The conjugate may also be linked to a CD25-binding peptide, which is attached to a polymer backbone. A microfluidic reactor is used to prepare the conjugate, and a sensor monitors the conjugation reaction. The treatment's efficacy is monitored by measuring biomarker levels in patient samples and adjusting the treatment regimen accordingly.
Novelty and Inventive Step
The new claims introduce a paradigm shift in targeted cancer therapy by combining the conjugate of formula (I) with advanced targeting moieties, companion diagnostics, and biomarker monitoring. This integration of components provides a more effective and personalized treatment approach, making the original inventive concept obsolete.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include using different targeting moieties, such as nanoparticles or liposomes, or varying the conjugate's formula to target different cancer cell receptors. The microfluidic reactor could be replaced with other conjugation methods, and the biomarker monitoring could be performed using different detection techniques.
Potential Commercial Applications and Market
The targeted cancer therapy with enhanced conjugate delivery has significant commercial potential in the oncology market, particularly for treating aggressive and hard-to-treat cancers. The market for cancer therapies is expected to grow significantly in the coming years, and this inventive concept is well-positioned to capture a share of that market.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K47/6807 |
| C | C07 | C07K16/2866 |
| A | A61 | A61K47/65 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Protein-small molecule therapeutic conjugates, specifically antibody-drug conjugates targeting cancer treatment, with expertise in chemical conjugation, targeting strategies, and molecular design for targeted therapeutics
Person of Ordinary Skill (PHOSITA) Profile
A skilled researcher with advanced degrees in biochemistry, molecular biology, or pharmaceutical sciences, having expertise in antibody engineering, drug conjugation techniques, cancer therapeutics, and microfluidic biotechnology
Obviousness Rationale
A PHOSITA would recognize that the PTD represents predictable variations on the source patent's core antibody-maytansine conjugate technology by applying known techniques in targeted drug delivery, companion diagnostics, and personalized medicine approaches. The disclosed modifications represent standard engineering strategies for enhancing therapeutic specificity and monitoring treatment efficacy. The combinations of targeting moieties, diagnostic components, and conjugation methods are well-established approaches in the field of targeted cancer therapeutics.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,637 |
|---|---|
| Title | Anti-CD25 antibody-maytansine conjugates and methods of use thereof |
| Assignee(s) | R.P. Scherer Technologies, LLC |